Amneal Pharmaceuticals, Inc.
AMRX evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $5.94B
- Lead Asset:
- imatinib (Approved)
What it means
What to watch
Prepared research question
What matters most for AMRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMRX
Amneal Pharmaceuticals, Inc. (AMRX) is a diversified, global biopharmaceutical company focused on affordable medicines, with a growing biosimilars business and a portfolio of approved complex injectables and Parkinson's disease treatments.
Key risk: High debt leverage
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 catalyst · 2 FDA decisions for Amneal Pharmaceuticals, Inc..
Amneal Pharmaceuticals, Inc. (AMRX) is a diversified, global biopharmaceutical company focused on affordable medicines, with a growing biosimilars business and a portfolio of approved complex injectables and Parkinson's disease treatments.
- Cash & equivalents of $127.6M as of 2026-06-30 [sec].
- Total revenue of $796.2M and net income of $57.7M as of 2026-06-30 [sec].
- Completed acquisition of Kashiv BioSciences in August 2026 to strengthen biosimilars presence [news · 2026-09-04].
- FDA approval and launch of lanreotide injection, a long-acting oncology product, in September 2026 [news · 2026-09-18].
- Launched two respiratory metered-dose inhalation products (albuterol sulfate and beclomethasone dipropionate) in the U.S. in April 2026 [news · 2026-04-14].
What works
- Approved Parkinson's disease products IPX203 (CREXONT) and ONGENTYS (opicapone) provide a stable revenue base [pipeline].
- Expanding biosimilars capability through the Kashiv acquisition positions Amneal to capitalize on the $300B+ global biologics loss-of-exclusivity opportunity [news · 2026-04-22].
- Recent FDA approval and immediate launch of lanreotide injection expands the complex injectables portfolio [news · 2026-09-18].
- Strong preliminary Q1 2026 financial results and raised full-year guidance indicate near-term growth momentum [news · 2026-04-22].
What to weigh
- Total debt of $2,684.3M as of 2026-06-30 is very high relative to shareholders' equity of $33.0M, indicating significant leverage [sec].
- The Kashiv acquisition will dilute existing stockholders' voting and economic interest by issuing 28,942,108 new shares [sec_mda · as of 2026-05-07].
- The pharmaceutical industry is highly competitive and highly regulated, creating ongoing operational challenges [sec_mda · as of 2026-05-07].
- Patent expiry for key product OPICAPONE (ONGENTYS) is scheduled for 2032-12-12, which may eventually open the market to generic competition [catalyst].
From the filings
Quoted directly from source documents.
Amneal completed the acquisition of Kashiv BioSciences in August 2026.
“On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences”
News · September 4, 2026
Amneal received FDA approval for lanreotide injection in September 2026.
“Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe.”
News · September 18, 2026
Amneal expects to meet or exceed its 2025 full-year financial guidance.
“Amneal Pharmaceuticals, Inc., a Delaware corporation ("Amneal" or the "Company"), intends to announce that it expects to meet or exceed its 2025 full-year financial guidance.”
News · January 13, 2026
Catalyst timeline
- 2032-12-12 · Patent_Expiry · OPICAPONE — Patent expiry for OPICAPONE (ONGENTYS) may allow generic competition, potentially affecting revenue from this Parkinson's disease product.
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $2,684.3M vs. equity of $33.0M as of 2026-06-30 [sec].
- Stockholder dilution from acquisition — Issuance of 28,942,108 new shares for Kashiv acquisition reduces existing stockholders' voting and economic interest [sec_mda · 2026-05-07].
- Patent expiry on key product — OPICAPONE (ONGENTYS) patent expires 2032-12-12, opening door to generic competition [catalyst].
- Regulatory and competitive pressure — Pharmaceutical industry is highly competitive and highly regulated, impacting results [sec_mda · 2026-05-07].
What to watch
- Integration and revenue contribution from the Kashiv BioSciences acquisition [news · 2026-09-04].
- Commercial performance of newly launched lanreotide injection and respiratory products [news · 2026-09-18] [news · 2026-04-14].
- Debt reduction progress given high leverage ratio [sec].
- Full-year 2026 financial results and any updated guidance [news · 2026-04-22].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Amneal Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Amneal Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 113.35 · 3% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~2250d
0 buys · 5 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 7.3
- Shares short
- 11,507,430
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. (AMRX) is a diversified, global biopharmaceutical company focused on affordable medicines, with a growing biosimilars business and a portfolio of approved complex injectables and Parkinson's disease treatments.
What is Amneal Pharmaceuticals, Inc.'s lead drug candidate?
Amneal Pharmaceuticals, Inc.'s most advanced tracked candidate is imatinib (Approved).
What is Amneal Pharmaceuticals, Inc.'s next catalyst?
Amneal Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA212489" — expected December 12, 2032.
Who is the CEO of Amneal Pharmaceuticals, Inc.?
Mr. Chirag K. Patel is the chief executive officer of Amneal Pharmaceuticals, Inc. (AMRX).
Where is Amneal Pharmaceuticals, Inc. headquartered?
Amneal Pharmaceuticals, Inc. (AMRX) is headquartered in Bridgewater, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.